Back to Search
THOMAS CLAY, D.O.
D.O.
Family Medicine Physician
NPI: 1902874191Individual
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
DO1929(NV)
Research & Publications (20)
Mortality probability model III and simplified acute physiology score II: assessing their value in predicting length of stay and comparison to APACHE IV.
PMID 19363210·Chest·2009
4-observational
Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium.
PMID 19259668·Cancer Immunol Immunother·2009
8-other
Relationship between discharge practices and intensive care unit in-hospital mortality performance: evidence of a discharge bias.
PMID 19536006·Med Care·2009
8-other
Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
PMID 19351755·Clin Cancer Res·2009
7-preclinical
Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity.
PMID 19229288·Cancer Gene Ther·2009
7-preclinical
Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines.
PMID 18519811·Blood·2008
3-trial
Detailed analysis of cytomegalovirus (CMV)-specific T cells expanded for adoptive immunotherapy of CMV infection following allogeneic stem cell transplantation for malignant disease.
PMID 18418774·Cytotherapy·2008
8-other
Results and harmonization guidelines from two large-scale international Elispot proficiency panels conducted by the Cancer Vaccine Consortium (CVC/SVI).
PMID 17721781·Cancer Immunol Immunother·2008
6-review
Trastuzumab signaling in ErbB2-overexpressing inflammatory breast cancer correlates with X-linked inhibitor of apoptosis protein expression.
PMID 18202008·Mol Cancer Ther·2008
8-other
Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system.
PMID 18280530·Virology·2008
8-other
Precision and linearity targets for validation of an IFNgamma ELISPOT, cytokine flow cytometry, and tetramer assay using CMV peptides.
PMID 18366814·BMC Immunol·2008
8-other
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.
PMID 18193223·Cancer Immunol Immunother·2008
8-other
Variation in ICU risk-adjusted mortality: impact of methods of assessment and potential confounders.
PMID 18403657·Chest·2008
8-other
Long term disease-free survival and T cell and antibody responses in women with high-risk Her2+ breast cancer following vaccination against Her2.
PMID 17822557·J Transl Med·2007
3-trial
Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy.
PMID 17373897·Expert Opin Biol Ther·2007
6-review
Investigation of HIFU-induced anti-tumor immunity in a murine tumor model.
PMID 17625013·J Transl Med·2007
7-preclinical
Update on anti-CTLA-4 antibodies in clinical trials.
PMID 17696822·Expert Opin Biol Ther·2007
6-review
CPG-7909 (PF-3512676, ProMune): toll-like receptor-9 agonist in cancer therapy.
PMID 17696823·Expert Opin Biol Ther·2007
6-review
Current immunotherapeutic strategies in colon cancer.
PMID 18022550·Surg Oncol Clin N Am·2007
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 4880 WYNN RD
LAS VEGAS, NV 89103 - Phone
- (702) 871-5005
Quick Facts
- NPI
- 1902874191
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile